Biblio
2023
Schroeder T, Stelljes M, Christopeit M, Esseling E, Scheid C, Mikesch J-H, Rautenberg C, Jäger P, Cadeddu R-P, Drusenheimer N, et al. Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial. Haematologica. 2023.
2019
Turki AT, Klisanin V, Bayraktar E, Kordelas L, Trenschel R, Ottinger H, Steckel NK, Tsachakis-Mück N, Leserer S, Ditschkowski M, et al. Optimizing anti-T-lymphocyte globuline dosing to improve long-term outcome after unrelated hematopoietic cell transplantation for hematologic malignancies. Am J Transplant. 2019.
Beelen DWilhelm, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet E-M, Hauptrock B, Dreger P, Luft T, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 . Lancet Haematol. 2019.